There has been a proliferation of patient-centric initiatives supporting drug development planning and execution during the past 24 to 36 months. Patient centricity seeks to engage patients and the health care community as drug development partners and represents a fundamental departure from a legacy product-centric research and development paradigm. As the clinical research enterprise gains experience, it is critical that it executes patient-centric initiatives well, provides sufficient support, sets realistic expectations and requires reasonable return on investment (ROI). This article offers insights and suggestions for organizations looking to establish ROI expectation and evaluation of their patient-centric initiatives. The article is based on ideas and concepts that have been shared and discussed among stakeholders throughout the clinical research enterprise.
机构:
Drug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USADrug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USA
Michaels, Debra L.
Lamberti, Mary Jo
论文数: 0引用数: 0
h-index: 0
机构:
Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USADrug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USA
Lamberti, Mary Jo
Pena, Yaritza
论文数: 0引用数: 0
h-index: 0
机构:
Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USADrug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USA
Pena, Yaritza
Kunz, Barbara Lopez
论文数: 0引用数: 0
h-index: 0
机构:
Drug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USADrug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USA
Kunz, Barbara Lopez
Getz, Kenneth
论文数: 0引用数: 0
h-index: 0
机构:
Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USADrug Informat Assoc, 21 Dupont Circle NW,Suite 300, Washington, DC 20036 USA